LabGenius announces research collaboration with Ablynx

By The Science Advisory Board staff writers

July 16, 2021 -- LabGenius has announced a research collaboration with Ablynx, a Sanofi company, for therapeutic proteins.

The company develops machine learning for protein engineering via its machine learning-driven evolution engine (EVA platform) and will combine its expertise with Ablynx's existing therapeutic Nanobody protein technology, it said. The optimized candidates will then be advanced by Ablynx into further validation studies.

Financial terms of the partnership were not disclosed.

Elektrofi, Takeda partner to advance plasma protein therapeutics
Biotechnology firm Elektrofi and Takeda Pharmaceuticals have partnered to advance high-concentration, low-viscosity protein therapeutics.
BrickBio advances conjugation platform for therapeutic development
BrickBio has demonstrated the power of its conjugation platform process for the commercial development of biologics in-house and with pharmaceutical partners.

Copyright © 2021 scienceboard.net


Conferences
Laboratory Products Association Annual Meeting
October 1-4
Scottsdale, Arizona United States
Cell & Gene Meeting on the Mesa
October 11-13
Carlsbad, California United States
IDWeek 2022
October 19-23
District of Columbia United States
American Society of Human Genetics Annual Meeting
October 25-29
Los Angeles, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter